Asesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción

dc.contributor.advisorMaldonado, Carlosspa
dc.contributor.advisorOrozco, Joséspa
dc.contributor.advisorLondoño, Daríospa
dc.contributor.authorArbeláez Ariza, Carlos Emiliospa
dc.contributor.orcidArbeláez Ariza, Carlos Emiliospa
dc.coverage.cityBogotá
dc.date.accessioned2024-01-29T18:24:52Z
dc.date.available2024-01-29T18:24:52Z
dc.date.issued2024-01
dc.descriptionilustraciones a blanco y negro, diagramasspa
dc.description.abstractAsesoría Farmacológica Para Prevenir Eventos Adversos En Una Unidad De Cuidados Intensivos En Un Hospital Universitario En Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción Se llevó a cabo un estudio observacional de cohorte en la Unidad de Cuidados Intensivos (UCI) del Hospital Universitario de San Ignacio entre julio y agosto de 2005, que incluyó 63 pacientes y registró 2209 órdenes médicas en 250 días-paciente de seguimiento. Se encontró que 54.9% de las órdenes iniciales y 32.3% de las órdenes de seguimiento presentaban errores de prescripción, siendo más comunes la administración de medicamentos contraindicados, interacciones de alto riesgo y el uso fuera de indicaciones aprobadas. Se encontró que las órdenes con estos errores tenían una frecuencia de efectos adversos del 32.9%, mientras que las órdenes sin errores mostraban un 22.9%. Estos datos sugieren que aproximadamente el 30.4% de los efectos adversos podrían haberse evitado mediante una intervención que identificara y previniera estos errores de prescripción. Además, se identificó que de los 110 medicamentos empleados en la UCI, diez causaron el 50% de los efectos adversos y veinticinco medicamentos el 80%. Se propone la intervención de un farmacólogo en la UCI para analizar las prescripciones, detener el uso de medicamentos contraindicados, prevenir interacciones de alto riesgo y corregir el uso fuera de indicaciones aprobadas. Esta intervención también incluiría la identificación temprana de errores de prescripción y eventos adversos, el apoyo en su manejo y el diseño de herramientas educativas continuas para mejorar los hábitos de prescripción médica y, por ende, la efectividad del tratamiento farmacológico en la UCI. (Texto tomado de la fuente)spa
dc.description.abstractPharmacological Counseling to Prevent Adverse Events in an Intensive Care Unit at a University Hospital in Bogotá PHASE 1: Frequency of Adverse Events and Prescription Errors An observational cohort study was conducted in the Intensive Care Unit (ICU) of San Ignacio University Hospital during July and August 2005. The study included 63 patients and recorded 2209 medical orders during 250 patient-days of follow-up. The findings revealed that 54.9% of the initial orders and 32.3% of the follow-up orders presented prescription errors, with the most common being administration of contraindicated medications, high-risk interactions, and off-label use. Orders with these errors showed an adverse effects frequency of 32.9%, while error-free orders displayed 22.9%. These results suggest that approximately 30.4% of adverse effects could have been prevented through intervention identifying and preventing these prescription errors. Furthermore, it was identified that ten medications caused 50% of the adverse effects, and twenty-five medications accounted for 80%, highlighting the importance of prioritizing these drugs in risk mitigation strategies. Consequently, the intervention of a pharmacologist in the ICU is proposed to analyze prescriptions, halt the use of contraindicated medications, prevent high-risk interactions, and correct off-label use. This intervention would also involve early identification of prescription errors and adverse events, support in their management, and the design of continuous educational tools to enhance medical prescription habits and thereby improve the effectiveness of pharmacological treatment in the ICU.eng
dc.description.degreelevelMaestríaspa
dc.description.degreenameMagíster en Ciencias - Farmacologíaspa
dc.description.methodsEl Hospital Universitario de San Ignacio ha implementado el sistema SAHI® de Historia Clínica Digital, permitiendo la consulta en tiempo real de la información de pacientes desde terminales internas. El estudio realizado es retrospectivo, basado en datos recopilados en tiempo real, sin contacto adicional con pacientes o personal médico. La vinculación de pacientes se realiza a través del sistema SAHI®, facilitando la búsqueda y seguimiento manual de pacientes hospitalizados, con datos registrados diariamente. La información se recopila en formularios y se transfiere manualmente a una base de datos en Excel, que luego se exporta a Minitab para el análisis. En cuanto a las definiciones de caso, se determina que un paciente experimenta un efecto adverso si presenta síntomas o variaciones negativas en pruebas diagnósticas después de la administración de un medicamento, sin explicación lógica relacionada con la patología del paciente. Los errores de prescripción se definen como desviaciones del uso racional del medicamento e incluyen indicación sin justificación, administración en contraindicación, errores posológicos y contraindicaciones que se asocian con toxicidad. La evaluación se realiza utilizando registros sanitarios, bases de datos como Micromedex®, y búsquedas bibliográficas. En términos de análisis estadístico, se emplea una fórmula de proporciones para determinar el tamaño muestral, ya que no se contaba con información previa sobre tasas de errores de medicación o frecuencia de efectos adversos. Las variables del paciente y las órdenes médicas se analizan descriptivamente, y se utilizan pruebas estadísticas como chi-cuadrado y regresión logística múltiple para explorar asociaciones entre variables y la presencia de errores de medicación.spa
dc.description.researchareaFarmacovigilanciaspa
dc.format.extentxiv, 84 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/85485
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.facultyFacultad de Cienciasspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Ciencias - Maestría en Ciencias - Farmacologíaspa
dc.relation.referencesHeard GC, Sanderson PM, Thomas RD. Barriers to adverse event and error reporting in anesthesia. Anesth Analg. 2012;114(3):604-614.spa
dc.relation.referencesBaillie M. An Account of a Particular Change of Structure in the Human Ovarium. L Med J. 1789;10:322-332spa
dc.relation.referencesWiedemann HR. [Indication of a current association of hypoplastic and aplastic limb malformations.]. Medizinische Welt. 1961;37:1863-1866.spa
dc.relation.referencesAuzépy P, Durocher A, Gay R, et al. [Severe drug complications: current prevalence amongst patients admitted to adult intensive care units (author’s transl)]. Nouv Press Med. 1979;8(16):1315-1318.spa
dc.relation.referencesFarina ML. Epidemiology of adverse drug reactions in intensive care units. A multicentre prospective survey. Italian Group on Intensive Care Evaluation (IGICE). Eur J Clin Pharmacol. 1987;31(5):507-512spa
dc.relation.referencesMichel P, Quenon JL, De Sarasqueta AM, Scemama O. Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals. BMJ. 2004;328(7433):199-202spa
dc.relation.referencesLaher AE, Enyuma CO, Gerber L, Buchanan S, Adam A, Richards GA. Medication Errors at a Tertiary Hospital Intensive Care Unit. Cureus. 2021;13(12): e20374spa
dc.relation.referencesAlbayrak A, Başgut B, Bıkmaz GA, Karahalil B. Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital. BMC Health Serv Res. 2022;22(1): 79spa
dc.relation.referencesSendekie AK, Kasahun AE, Limenh LW, Dagnaw AD, Belachew EA. Clinical and economic impact of adverse drug reactions in hospitalised patients: prospective matched nested case-control study in Ethiopia. BMJ Open. 2023;13(6): e073777spa
dc.relation.referencesda Costa TX, de Almeida Pimenta Cunha MD, do Vale Bezerra PK, Azeredo FJ, Martins RR, Oliveira AG. Incidence of Adverse Drug Reactions in High-Risk Pregnancy: A Prospective Cohort Study in Obstetric Intensive Care. Eur J Clin Pharmacol. 2020;76(2):291-298.spa
dc.relation.referencesNazer LH, Hawari F, Al-Najjar T. Adverse drug events in critically ill patients with cancer: incidence, characteristics, and outcomes. J Pharm Pract. 2014;27(2):208-213.spa
dc.relation.referencesBenkirane RR, R-Abouqal R, Haimeur CC, et al. Incidence of adverse drug events and medication errors in intensive care units: a prospective multicenter study. J Patient Saf. 2009;5(1):16-22.spa
dc.relation.referencesKosenow W, Pfeiffer RA. Micromelia, Haemangioma und Duodenal Stenosis Exhibit, German Pediatric Society, Kassel, 1960. Monatsschr Kinderheilkd. 1961;109:227.spa
dc.relation.referencesUMC. About the WHO Programme for International Drug Monitoring. Accessed December 27, 2023. https://who-umc.org/about-the-who-programme-for-international-drug-monitoring/spa
dc.relation.referencesUMC. The beginner’s guide to pharmacovigilance. Published 2023. Accessed December 27, 2023. https://who-umc.org/about-the-who-programme-for-international-drug-monitoring/the-beginner-s-guide-to-pharmacovigilance/spa
dc.relation.referencesBrown S, Black K, Mrochek S, et al. RADARx: Recognizing, Assessing, and Documenting Adverse Rx events. Proc AMIA Symp. Published online 2000:101-105.spa
dc.relation.referencesBates DW, Cullen DJ, Laird N, et al. Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention. JAMA. 1995;274(1):29-34.spa
dc.relation.referencesLeape LL, Bates DW, Cullen DJ, et al. Systems Analysis of Adverse Drug Events. JAMA. 1995;274(1):35-43.spa
dc.relation.referencesLeape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267-270.spa
dc.relation.referencesGurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109(2):87-94.spa
dc.relation.referencesKaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285(16):2114-2120.spa
dc.relation.referencesFortescue EB, Kaushal R, Landrigan CP, et al. Prioritizing strategies for preventing medication errors and adverse drug events in pediatric inpatients. Pediatrics. 2003;111(4 Pt 1):722-729.spa
dc.relation.referencesSuggested definitions and relationships among medication misadventures, medication errors, adverse drug events, and adverse drug reactions. Am J Health Syst Pharm. 1998;55(2):165-166spa
dc.relation.referencesSERVICES DOHAH. Guideline for Postmarketing Reporting of Adverse Drug Experiences.; 1992. https://www.fda.gov/media/83280/downloadspa
dc.relation.referencesEdwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet (London, England). 2000;356(9237):1255-1259spa
dc.relation.referencesCobert B, Biron P. Pharmacovigilance from a to Z : Adverse Drug Event Surveillance. Blackwell Science; 2002spa
dc.relation.referencesHarmonisation International Conference on. E 2 D: Postapproval Safety Data Management.; 2003. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-topic-e-2-d-postapproval-safety-data-management-step-5_en.pdfspa
dc.relation.referencesClassen DC, Pestotnik SL, Evans RS, Burke JP. Computerized Surveillance of Adverse Drug Events in Hospital Patients. JAMA. 1991;266(20):2847-2851spa
dc.relation.referencesSchlienger RG, Lüscher TF, Schoenenberger RA, Haefeli WE. Academic detailing improves identification and reporting of adverse drug events. Pharm World Sci. 1999;21(3):110-115.spa
dc.relation.referencesAndrews LB, Stocking C, Krizek T, et al. An alternative strategy for studying adverse events in medical care. Lancet (London, England). 1997;349(9048):309-313spa
dc.relation.referencesInstitute of Medicine (US) Committee on Quality of Health Care in America. To Err Is Human: Building a Safer Health System. (Kohn LT, Corrigan JM, Molla S. D, eds.). National Academy of Sciences; 2000spa
dc.relation.referencesWorld Health Organization. The Importance of Pharmacovigilance: An Essential Tool. World Health Organization; 2002.spa
dc.relation.referencesUMC. Glossary of Pharmacovigilance Terms.; 2022. https://learning.who-umc.org/files/114398/SCORM_867007413/scormdriver/indexAPI.htmlspa
dc.relation.referencesBates DW, Boyle DL, Vliet MBV, Schneider J, Leape L. Relationship between medication errors and adverse drug events. J Gen Intern Med. 1995;10(4):199-205.spa
dc.relation.referencesEbbesen J, Buajordet I, Erikssen J, et al. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001;161(19):2317-2323.spa
dc.relation.referencesHutchinson TA, Flegel KM, Kramer MS, Leduc DG, Kong HHP. Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis. 1986;39(7):533-542. doi:10.1016/0021-9681(86)90198-0spa
dc.relation.referencesPutriana NA, Rusdiana T, Rostinawati T, Akbar MR, Destiani DP. Evaluation of adverse drug reaction in patients warfarin therapy. J Adv Pharm Technol Res. 2022;13(4):291-295.spa
dc.relation.referencesMartys CR. Adverse reactions to drugs in general practice. Br Med J. 1979;2(6199):1194-1197spa
dc.relation.referencesEjeta F, Aferu T, Feyisa D, et al. Adverse Drug Reaction and Its Predictors Among Psychiatric Patients Taking Psychotropic Medications at the Mizan-Tepi University Teaching Hospital. Neuropsychiatr Dis Treat. 2021;17:3827-3835spa
dc.relation.referencesAbah IO, Dayom WD, Dangiwa DA, et al. Comparative incidence of adverse drug reaction during the first and subsequent year of antiretroviral therapy in a Nigerian HIV infected Cohort. Afr Health Sci. 2021;21(3):1027-1039spa
dc.relation.referencesSankhi S, Marasine NR, Sankhi S, Lamichhane R. Adverse Drug Reaction due to Antidepressants among Patients with Depression in a Private Psychiatric Hospital of Nepal. Biomed Res Int. 2020; 16:2020:6682928spa
dc.relation.referencesClassen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse Drug Events in Hospitalized Patients: Excess Length of Stay, Extra Costs, and Attributable Mortality. JAMA. 1997;277(4):301-306.spa
dc.relation.referencesLazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies. JAMA. 1998;279(15):1200-1205.spa
dc.relation.referencesDavies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2): e4439spa
dc.relation.referencesRunciman WB, Roughead EE, Semple SJ, Adams RJ. Adverse drug events and medication errors in Australia. Int J Qual Heal care J Int Soc Qual Heal Care. 2003;15 Suppl 1(SUPPL. 1): i49-59.spa
dc.relation.referencesSeddon ME, Jackson A, Cameron C, et al. The Adverse Drug Event Collaborative: a joint venture to measure medication-related patient harm. N Z Med J. 2012;126(1368):9-20spa
dc.relation.referencesVargas E, Terleira A, Hernando F, et al. Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med. 2003;31(3):694-698.spa
dc.relation.referencesHallas J, Gram L, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol. 1992;33(1):61-68spa
dc.relation.referencesHoward RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12(4):280-285spa
dc.relation.referencesCooke DI, van der Merwe W, Pudifin DJ. Hospital admissions for adverse reactions to drugs and deliberate self-poisoning. S Afr Med J. 1985;67(19):770-772spa
dc.relation.referencesCaranasos GJ, Stewart RB, Cluff LE. Drug-induced illness leading to hospitalization. JAMA. 1974;228(6):713-717spa
dc.relation.referencesRostin M, Pascaud A, Lauque D, Sorbette F, Carles P, Montastruc JL. [An intensive survey of drug surveillance in a medical admissions department]. La Rev Med interne. 1987;8(2):173-179spa
dc.relation.referencesHallas J, Haghfelt T, Gram LF, Grodum E, Damsbo N. Drug related admissions to a cardiology department; frequency and avoidability. J Intern Med. 1990;228(4):379-384spa
dc.relation.referencesLakshmanan MC, Hershey CO, Breslau D. Hospital admissions caused by iatrogenic disease. Arch Intern Med. 1986;146(10):1931-1934spa
dc.relation.referencesEinarson TR, Gutierrez LM, Rudis M. Drug-related hospital admissions. Ann Pharmacother. 1993;27(7-8):832-840spa
dc.relation.referencesKarande S, Gogtay NJ, Kshirsagar NA. Improving drug safety monitoring. Indian Pediatr. 2003;40(12):1167-1175.spa
dc.relation.referencesWinterstein AG, Sauer BC, Hepler CD, Poole C, Suárez EC, Kaiser JM. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7-8):1238-1248.spa
dc.relation.referencesMcDonnell PJ, Jacobs MR, Monsanto HA, Kaiser JM. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9):1331-1336spa
dc.relation.referencesSchneider PJ, Gift MG, Lee YP, Rothermich EA, Sill BE. Cost of medication-related problems at a university hospital. Am J Health Syst Pharm. 1995;52(21):2415-2418.spa
dc.relation.referencesBates DW, Spell N, Cullen DJ, et al. The Costs of Adverse Drug Events in Hospitalized Patients. JAMA. 1997;277(4):307-311spa
dc.relation.referencesWhite TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999;15(5):445-458.spa
dc.relation.referencesPotts AL, Barr FE, Gregory DF, Wright L, Patel NR. Computerized physician order entry and medication errors in a pediatric critical care unit. Pediatrics. 2004;113(1 Pt 1):59-63spa
dc.relation.referencesKaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285(16):2114-2120spa
dc.relation.referencesBurnum JF. Letter: Preventability of adverse drug reactions. Ann Intern Med. 1976;85(1):80-81spa
dc.relation.referencesPorter J, Jick H. Drug-related deaths among medical inpatients. JAMA. 1977;237(9):879-881spa
dc.relation.referencesMelmon KL. Preventable drug reactions--causes and cures. N Engl J Med. 1971;284(24):1361-1368spa
dc.relation.referencesBates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med. 1993;8(6):289-294spa
dc.relation.referencesGurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107-1116spa
dc.relation.referencesField TS, Gurwitz JH, Harrold LR, et al. Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Inform Assoc. 2004;11(6):492-498spa
dc.relation.referencesSilva CMD da, Besen BAMP, Nassar AP. Characteristics of critically ill patients with cancer associated with intensivist’s perception of inappropriateness of ICU admission: A retrospective cohort study. J Crit Care. 2024;79:154468spa
dc.relation.referencesSánchez-Sánchez MM, Campos-Asensio C, Arias-Rivera S. Workloads of intensive care nurses. Validity of their estimation using mobile applications and comparison with Nursing Activities Score. Systematised review of the literature. Enferm intensiva. Published online December 12, 2023spa
dc.relation.referencesLeviatan I, Oberman B, Zimlichman E, Stein GY. Associations of physicians’ prescribing experience, work hours, and workload with prescription errors. J Am Med Inform Assoc. 2021;28(6):1074-1080.spa
dc.relation.referencesOliveira AC de, Garcia PC, Nogueira L de S. Nursing workload and occurrence of adverse events in intensive care: a systematic review. Rev Esc Enferm USP. 2016;50(4):683-694.spa
dc.relation.referencesDagdelen MS, Gulen D, Ceylan I, Girgin NK. Evaluation of potential drug-drug interactions in intensive care unit. Eur Rev Med Pharmacol Sci. 2021;25(18):5801-5806spa
dc.relation.referencesArab A, Sheikh-Germchi Z, Habibzadeh S, Sadeghiye-Ahari S, Mostafalou S. Frequency, Predictors, and Outcomes of the Potential Drug-Drug Interactions in the ICUs of Teaching Hospitals in Ardabil, Northwest of Iran During 2019-2020. Hosp Pharm. 2023;58(5):484-490spa
dc.relation.referencesKlopotowska JE, Leopold JH, Bakker T, et al. Adverse drug events caused by three high-risk drug-drug interactions in patients admitted to intensive care units: A multicentre retrospective observational study. Br J Clin Pharmacol. 2024;90(1):164-175spa
dc.relation.referencesCantor N, Durr KM, McNeill K, et al. Increased Mortality and Costs Associated with Adverse Events in Intensive Care Unit Patients. J Intensive Care Med. 2022;37(8):1075-1081spa
dc.relation.referencesHouso A, Hamdan M, Falana H. Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2022;30(12):1718-1724spa
dc.relation.referencesAlghamdi AA, Keers RN, Sutherland A, Ashcroft DM. Prevalence and Nature of Medication Errors and Preventable Adverse Drug Events in Paediatric and Neonatal Intensive Care Settings: A Systematic Review. Drug Saf. 2019;42(12):1423-1436spa
dc.relation.referencesResnik DB, Stewart CN. Misconduct versus honest error and scientific disagreement. Account Res. 2012;19(1):56-63spa
dc.relation.referencesLiker JK. The Toyota Way: 14 Management Principles from the World’s Greatest Manufacturer. 2 ED. McGraw-Hill; 2021.spa
dc.relation.referencesJeremy LE, Soong JL, Lie SA. A cost avoidance study of critical care pharmacists’ interventions in a tertiary institution in Singapore. Am J Health Syst Pharm. 2023;80(5):267-283spa
dc.relation.referencesAlthomali A, Altowairqi A, Alghamdi A, et al. Impact of Clinical Pharmacist Intervention on Clinical Outcomes in the Critical Care Unit, Taif City, Saudi Arabia: A Retrospective Study. Pharm (Basel, Switzerland). 2022;10(5):108spa
dc.relation.referencesMuñoz-Pichuante D, Villa-Zapata L. Benefit of Incorporating Clinical Pharmacists in an Adult Intensive Care Unit: A Cost-saving Study. J Clin Pharm Ther. 2020;45(5):1127-1133spa
dc.relation.referencesLeache L, Aquerreta I, Aldaz A, Monedero P, Idoate A, Ortega A. Clinical and economic impact of clinical pharmacist interventions regarding antimicrobials on critically ill patients. Res Social Adm Pharm. 2020;16(9):1285-1289spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/spa
dc.subject.ddc610 - Medicina y salud::615 - Farmacología y terapéuticaspa
dc.subject.decsUnidades de cuidados intensivosspa
dc.subject.decsIntensive care unitseng
dc.subject.decsNegativa del paciente al tratamientospa
dc.subject.decsTreatment refusaleng
dc.subject.decsCumplimiento de la medicaciónspa
dc.subject.decsMedication adherenceeng
dc.subject.decsErrores de medicaciónspa
dc.subject.decsMedication errorseng
dc.subject.proposalUnidad de cuidados intensivosspa
dc.subject.proposalEventos adversosspa
dc.subject.proposalPrevenciónspa
dc.subject.proposalErrores de medicaciónspa
dc.subject.proposalIntensive care uniteng
dc.subject.proposalAdverse eventseng
dc.subject.proposalPreventioneng
dc.subject.proposalMedication errorseng
dc.titleAsesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripciónspa
dc.title.translatedPharmacological Counseling to Prevent Adverse Events in an Intensive Care Unit at a University Hospital in Bogotá PHASE 1: Frequency of Adverse Events and Prescription Errorseng
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentEstudiantesspa
dcterms.audience.professionaldevelopmentInvestigadoresspa
dcterms.audience.professionaldevelopmentMaestrosspa
dcterms.audience.professionaldevelopmentPúblico generalspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
79952694.2007.pdf
Tamaño:
940.88 KB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Maestría en Ciencias - Farmacología

Bloque de licencias

Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
5.74 KB
Formato:
Item-specific license agreed upon to submission
Descripción: